
The Verge: Anthropic’s IPO filing lays out a plan to ‘revolutionize every area of human endeavor’ with AI
Anthropic has filed its S-1 prospectus with the Securities and Exchange Commission, preparing the company behind Claude to beat OpenAI to the punch with an IPO. In a filing with the SEC, Anthropic said it plans to list on the Nasdaq exchange under the ticker symbol "ANT." The AI company confidentially filed with the SEC earlier this year in June, but the public document reveals more details, as well as the company's plans for the future in its own words, as well as potential r
Anthropic, the AI company behind Claude, filed its S-1 prospectus with the Securities and Exchange Commission to go public on the Nasdaq exchange under the ticker symbol ANT. The filing reveals the company had an $80.7 billion net loss on $16.3 billion in revenue in the first half of the year and has not yet become profitable. Anthropic describes AI as one of the most consequential technologies in human history while acknowledging significant risks including potential existential dangers, misuse for cyberattacks or biological weapons, and loss of control over advanced systems.
The IPO filing reveals Anthropic's financial performance and the substantial risks the company faces, from competition and compute availability to concerns about advanced AI systems. The prospectus shows how Anthropic plans to balance realizing AI's potential benefits while managing its dangers as it seeks to go public.
Anthropic, the AI company behind Claude, has filed paperwork with the Securities and Exchange Commission to go public on the Nasdaq exchange under the ticker symbol "ANT," aiming to complete its initial public offering before a competitor does. According to the filing, the company had an $80.7 billion net loss on $16.3 billion in revenue in the first half of the year. Anthropic describes AI as one of the most consequential technologies in human history with potential to accelerate scientific innovation, increase economic growth, and solve longstanding problems, while also acknowledging significant risks that must be addressed. The company has indicated that its behavior may differ from that of a purely profit-maximizing company as it seeks to realize AI's benefits while managing its dangers.
Want to go deeper than the news? Explore live, cohort-based AI courses taught by practitioners.
Browse AI courses on Maven
Anthropic has officially filed for an IPO, revealing soaring revenue, mounting losses, major enterprise adoption, and an unusual governance structure designed to preserve founder control and its AI safety mission.
Also reported by SiliconANGLE, Wired AI and Crunchbase News

Should OpenAI command an over $1 trillion valuation with this round, it would break records as the most highly valued private company ever.
Also reported by SiliconANGLE and The Decoder

Bedrock Robotics automates large excavators to improve construction site economics. | Credit: Bedrock Robotics San Francisco-based Bedrock Robotics has raised $600 million in Series C funding, co-led by CapitalG and Emergence Capital, at a $4.1 billion valuation. The round brings its total funding to nearly $1 billion as it scales fully autonomous heavy equipment to address nationwide construction labor shortages. The round included new investors US Innovative Technology Fund (USIT), Bessemer Ve

Anthropic has finally filed its S-1 prospectus with the SEC, a document designed to give investors a look under the hood of its business, from how much its executives are making and plans for spending its IPO billions to the risks that could derail its ambitions. At more than 300 pages, there's a lot to unpack, and some of the disclosures have not previously been reported. Here are some of the biggest things that jumped out to us from our first pass: It pays to be an Amodei Sib

DeepSeek has reportedly raised $15 billion in one of China's largest funding rounds, just days after the US ordered federal agencies to remove its technology over national security concerns.

OpenAI is acquiring startup Orchestra Bio and plans to merge it with its life sciences AI platform Rosalind. The goal is to build AI agents that help pharma teams coordinate drug development, from tracking trials to spotting problems. Developing a new drug in the US takes ten to 15 years on average. OpenAI already works with Novo Nordisk and Moderna on AI-driven pharma research. The article OpenAI acquires Orchestra Bio to build AI agents that speed up drug development appeared first on